سعر انتيكول 20 مجم 10 اقراص 2022

Antichol 20 (atorvastatin 20 mg) film-coated tablets, an HMG-CoA reductase inhibitor (statin) lipid-lowering agent by Jedco International Co. for Pharmaceuticals, Egypt; pack of 10 tablets.

• Primary hypercholesterolaemia (including heterozygous familial hypercholesterolaemia) or combined (mixed) hyperlipidaemia, as an adjunct to diet to reduce elevated total cholesterol, LDL-C, apolipoprotein B and triglyceridesPopulation: Adults, adolescents and children 10 years and olderelectronic medicines compendium (eMC)
• Homozygous familial hypercholesterolaemia, as an adjunct to other lipid-lowering treatments (e.g. LDL apheresis) or if such treatments are unavailablePopulation: Adultselectronic medicines compendium (eMC)
• Prevention of cardiovascular events in patients estimated to have a high risk for a first cardiovascular event, as an adjunct to correction of other risk factorsPopulation: Adultselectronic medicines compendium (eMC)

• Common: nasopharyngitis, allergic reactions, hyperglycaemia, headache, pharyngolaryngeal pain, epistaxis, constipation, flatulence, dyspepsia, nausea, diarrhoea, myalgia, arthralgia, pain in extremity, muscle spasms, joint swelling, back pain, abnormal liver function tests, increased blood CK. Rare but serious: myopathy, myositis, rhabdomyolysis, hepatitis, cholestasis, severe skin reactions.International label, same formulation · electronic medicines compendium (eMC)

• Hypersensitivity to atorvastatin or any excipient; active liver disease or unexplained persistent serum transaminase elevation exceeding 3 times the upper limit of normal; pregnancy, breast-feeding and women of child-bearing potential not using appropriate contraception; concomitant glecaprevir/pibrentasvir.International label, same formulation · electronic medicines compendium (eMC)
• US label: acute liver failure or decompensated cirrhosis; hypersensitivity to atorvastatin or any excipient.International label, same formulation · DailyMed (U.S. National Library of Medicine)

• Liver function tests should be performed before treatment and periodically thereafter; reduce the dose or withdraw if transaminases persistently exceed 3 times the upper limit of normal; caution with substantial alcohol intake or history of liver disease.International label, same formulation · electronic medicines compendium (eMC)
• Myopathy and rarely rhabdomyolysis can occur, and very rarely immune-mediated necrotising myopathy; measure CK before treatment in patients with predisposing factors (renal impairment, hypothyroidism, personal/family history of muscle disorders, previous statin/fibrate muscle toxicity, liver disease, age over 70); stop if CK exceeds 10 times the upper limit of normal or muscle symptoms are severe.International label, same formulation · electronic medicines compendium (eMC)
• Must not be co-administered with systemic fusidic acid or within 7 days of stopping it (risk of rhabdomyolysis, including fatal cases); avoid or use lower doses with strong CYP3A4 inhibitors or transport protein inhibitors.International label, same formulation · electronic medicines compendium (eMC)

• Strong CYP3A4 inhibitors (clarithromycin, itraconazole, HIV protease inhibitors) and ciclosporinMarkedly increase atorvastatin exposure and myopathy risk; avoid if possible or use lower doses with clinical monitoring (ciclosporin: avoid).electronic medicines compendium (eMC)
• Glecaprevir/pibrentasvirContraindicated.electronic medicines compendium (eMC)
• Elbasvir/grazoprevir, letermovirDo not exceed atorvastatin 20 mg daily.electronic medicines compendium (eMC)

• Contraindicated in pregnancy; women of child-bearing potential should use appropriate contraception. Rare reports of congenital anomalies after intrauterine exposure to HMG-CoA reductase inhibitors; animal studies showed reproductive toxicity.International label, same formulation · electronic medicines compendium (eMC)
• Contraindicated during breast-feeding (serious adverse reactions possible in the infant).International label, same formulation · electronic medicines compendium (eMC)

• Atorvastatin: Selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme of cholesterol synthesis; lowers plasma cholesterol and increases hepatic LDL receptors, enhancing LDL uptake and catabolism.